A multidisciplinary team (MDT) approach is necessary in treating metastatic breast cancer in order to provide optimal care. This article, published in JNCCN, reviews the findings of an educational needs assessment of the multidisciplinary breast cancer management team.
As treatment options increase, patient-reported outcomes and cost-effective analyses will play a key role in determining how drugs are sequenced in clinical practice.
Targeted and immunotherapies appear to be opening a new frontier in the management of elderly patients.
In serious breach cases, the HHS Office for Civil Rights may impose CAPs to prevent breaches from recurring.
Researchers argue that children with CML should receive different treatments than adults, which may mitigate long-term side effects.
Gastrinomas, rare endocrine tumors, can be treated in multiple ways, regardless of whether the tumor is resectable.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Immunotherapy in the Twentieth Century: William Coley and Lloyd J. Old
- Industry Payments Influence Research, Prescribing, and Advocacy
- The Rising Trend of Colorectal Cancer in Young Adults
- In-House Specialty Pharmacies Improve Quality of Care
- TKIs Linked to Pulmonary Hypertension in CML
- Meningioma Incidence After Cranial Radiotherapy for Pediatric Cancer
- Short Telomeres Predict Poor Survival in Multiple Myeloma
- Nivolumab for Advanced Renal Cell Carcinoma: Cost and Value
- HRQOL, Not Outcomes, Differ Between United States and Chile in Osteosarcoma